All In Biotech

Drug Trial Radar · NCT03430284

Multifactorial Intervention on Diabetes (MIDiab Study)

Effects of Multifactorial Intervention on Type 2 Diabetes - A Multicenter, Open-Label, Randomized, Parallel Controlled, Community Trial.

Last checked: Nov 20, 2026Latest source record: Jul 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 6,300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

6,300

Planned (sponsor's estimate)

Start

Apr 1, 2018

Primary completion

Dec 31, 2021

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Shandong Provincial HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
The Affiliated Hospital of Qingdao University; The First Hospital of Jilin University; The First People's Hospital of Yinchuan; Beijing Hospital, National Center of Gerontology; The First Affiliated Hospital of Air Force Medical University; Inner Mongolia People's Hospital; The Affiliated Hospital of Inner Mongolia Medical University; Fujian Medical University Union Hospital; The Fourth Affiliated Hospital of Harbin Medical University; Yantai Yuhuangding Hospital
First posted
Feb 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 35 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The prevalence of diabetes mellitus has been increasing in recent decades in China, and vascular complication is the major burden in patients with type 2 diabetes. Previous studies demonstrated that only glycemic control was not effective enough to prevent or improve diabetic vascular complications, but guidelines from the Chinese Diabetes Society and other national guidelines recommend an integrated multifactorial treatment approach. In this study, we aim to evaluate the effect on diabetic vascular complications of a multifactorial intervention comprising behavior modification, polypharmacological therapy and periodical monitoring in patients with type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Lifestyle therapyBehavioral

    The key components of lifestyle therapy include medical nutrition therapy, regular physical activity, sufficient amounts of sleep, behavioral support, and smoking cessation and avoidance of all tobacco products.

  • PharmacotherapyDrug

    Pharmacological therapy is individualized. 1.Glucose-lowering agents: 1. Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors 2. GLP-1 receptor agonist 3. Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products 2.Blood pressure-lowering agents (1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers 3.Lipid-modifying agents (1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc. 4.Medications for weight management (1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels.

  • Monitoring and managementOther

    Before follow-up, patients are divided into low, moderate or high risk for diabetic vascular complications. During follow-up, frequencies of interview and risk factor monitoring are formulated based on the risk stratification.

  • General treatmentOther

    General treatment is carried out based on the device from the general practitioners at present.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Integrated management rate of multiple risk factor in type 2 diabetesTime frame: 30 months
  2. Incidence of diabetic vascular complicationsTime frame: 30 months
  3. Control rate of diabetes and diabetic vascular complicationsTime frame: 30 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shandong Provincial Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Shandong Provincial Hospital

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.